Standout Papers

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and t... 1997 2026 2006 2016 501
  1. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. (1997)
    Franco M. Muggia, John D. Hainsworth et al. Journal of Clinical Oncology

Immediate Impact

4 by Nobel laureates 5 from Science/Nature 81 standout
Sub-graph 1 of 20

Citing Papers

Novel approaches for vaccine development
2021 Standout
Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy
2021 Standout
15 intermediate papers

Works of L Roman being referenced

Phase II Study of Liposomal Doxorubicin in Advanced Gynecologic Cancers
2000
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
1997 Standout

Author Peers

Author Last Decade Papers Cites
L Roman 286 54 67 271 216 9 662
Agustin Garcia 261 88 55 252 196 6 693
Linda J. Paradiso 244 65 36 245 202 20 688
Vito Carone 131 49 27 303 200 12 583
Birgit Volgger 250 45 11 359 204 17 620
Yung‐Kwei Soong 240 44 21 73 132 13 810
Charlotte E.S. Hoogstins 234 212 120 111 183 15 843
E. Sandberg 375 160 35 202 218 16 736
M. Phillips 323 68 10 228 247 9 611
E. A. te Velde 179 115 43 70 268 17 689
Steve Swenson 216 106 17 248 91 19 643

All Works

Loading papers...

Rankless by CCL
2026